Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-019250
Filing Date
2016-05-12
Accepted
2016-05-12 16:34:54
Documents
50
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ogxi-10q_20160331.htm 10-Q 1193774
2 EX-31.1 ogxi-ex311_6.htm EX-31.1 9040
3 EX-31.2 ogxi-ex312_8.htm EX-31.2 9027
4 EX-32.1 ogxi-ex321_7.htm EX-32.1 4824
5 EX-32.2 ogxi-ex322_9.htm EX-32.2 4799
6 GRAPHIC geypfegtaecb000001.jpg GRAPHIC 2998
  Complete submission text file 0001564590-16-019250.txt   4436001

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT ogxi-20160331.xml EX-101.INS 838296
8 XBRL TAXONOMY EXTENSION SCHEMA ogxi-20160331.xsd EX-101.SCH 35893
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ogxi-20160331_cal.xml EX-101.CAL 37675
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ogxi-20160331_def.xml EX-101.DEF 132344
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE ogxi-20160331_lab.xml EX-101.LAB 293436
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ogxi-20160331_pre.xml EX-101.PRE 232102
Mailing Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011
Business Address 19820 NORTH CREEK PARKWAY SUITE 201 BOTHELL WA 98011 425-686-1500
ONCOGENEX PHARMACEUTICALS, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 161644458
SIC: 2835 In Vitro & In Vivo Diagnostic Substances